

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
National Jewish Health	41st Annual National Jewish Health Pulmonary and Allergy Update	15,000 ³
University of Louisville Research Foundation, Inc., Global Academy for Medical Education; Postgraduate Institute for Medicine	18th Annual Caribbean Dermatology Symposium	10,000 ³
University of Nevada, Reno School of Medicine; Foundation for Research and Education in Dermatology	2019 Winter Clinical Dermatology Conference Live and Enduring CME Satellite: Atopic Dermatitis: Management of Problem Cases	150,000 ³
Regents of the University of Minnesota; University of Minnesota	MPSI Newborn Screening Educational Meeting	93,200
Federation of American Societies for Experimental Biology	The Endoplasmic Reticulum (ER) Conference: From Unfolded Proteins to Disease	5,000
USF Health Professions Conferencing Corporation	2019 Symposium Update in Allergy and Immunology	5,000 ³
American College of Allergy, Asthma & Immunology; Western Society of Allergy, Asthma & Immunology	WSAAI 2019: 57th Annual Scientific Session	20,000 ³
AKH, Inc.; Catalyst Medical Education, LLC	Strategies to Improving the Diagnosis, Treatment, and Management of Patients with Lysosomal Storage Diseases	100,000
i3 Health	2019 ASCO Rapid Reporter: Key Data and Analyses in Genitourinary Cancers	20,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
UMA Education dba Global Education Group; Integritas Communications	Looking Under the Surface in Pediatric Atopic Dermatitis: Collaborative Care for Better Patient Outcomes	617,451 ³
Research to Practice	The 1st Annual General Medical Oncology Education Summit — A Pilot Multitumor CME Conference for Practicing Oncologists: Prostate Cancer Module	25,000
Physicians' Education Resource, LLC (PER)	2019 New York GU™: 12th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies	25,000
The Omnia Prova Education Collaborative (TOPEC); Prova Education, Inc.	Updates in Hemophilia Care: Optimizing Treatment Individualization in a Multidisciplinary Setting	75,000
The Regents of the University of California	University of California, Irvine Lysosomal Storage Diseases Program Health Care Providers Educational Grant	46,892
Continuing Education Alliance; Practicing Clinicians Exchange	Practicing Clinicians Exchange (PCE) Oncology Briefcase: Navigating the Treatment Landscape in Men with Nonmetastatic and Metastatic Castration-Resistant Prostate Cancer	20,000
Oakstone Publishing; Answers in CME Inc.	The Power of Prevention: Lipid-Lowering Strategies for Cardiovascular Risk Reduction	375,000 ³
National Lipid Association; RMEI	PCSK9s: When, Why, and How?	305,210 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
PESI, Inc.	16th Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease	50,000
Consortium of Multiple Sclerosis Centers; The France Foundation	A Practical Guide to Rehabilitation in MS: Second Edition an Advances In Multiple Sclerosis (AIMS) Primer	75,000
Consortium of Multiple Sclerosis Centers; International Organization of MS Nurses	MS Nursing 2019: Voices Will Be Heard	75,000
Physicians' Education Resource, LLC (PER)	2019 CMSC: Considerations in Treatment Efficacy of Multiple Sclerosis and Emerging Agents: What is Best for Your Patient?	100,000
The France Foundation	Attacking RRMS and SPMS: Employing Key Clinical and Patient Considerations	10,000
Physicians' Education Resource, LLC (PER)	Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right Time	40,000
American Society of Clinical Oncology	2019 Genitourinary (GU) Cancers Symposium: Translating Evidence to Multidisciplinary Care	30,000
Postgraduate Institute for Medicine; Enquiring Minds, LLC	Tailoring Treatment Plans for Metastatic Hormone-Sensitive Prostate Cancer: Expert Guidance on Applying Clinical Advances to Clinical Practice	45,000
i3 Health	Optimizing Treatment Experiences in Castration-Resistant Prostate Cancer	45,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
National Association of Managed Care Physicians	New Treatment Paradigms in Castration-Resistant Prostate Cancer: Enhancing Care through Emerging Diagnostics and Novel Therapies	45,000
Association of Black Cardiologists, Inc.	3rd Annual Conversations in Primary Care 2019 Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care	70,500 ³
Medical College of Wisconsin	Clinical Genetics Nurse Practitioner Conference	10,000
Oakstone Publishing; Answers in CME Inc.	Downsizing the Diagnostic Delay of Fabry Disease: Optimizing Outcomes Via Early Recognition	125,000
National Association of Managed Care Physicians	Recent Advances in the Treatment and Management of Moderate-to-Severe Atopic Dermatitis: What's New in Biologic Therapies	57,000 ³
American College of Cardiology Foundation	Practical Application of the New Cholesterol Guideline: Assessing Risk and Optimizing Therapies	50,000 ³
Annenberg Center for Health Sciences at Eisenhower	Expert Perspectives: A Pathophysiologic Basis for Evidence-Based Treatment of Moderate-Severe Atopic Dermatitis	190,000 ³
Medical Learning Institute, Inc.; PVI, PeerView Institute for Medical Education	PeerView in Session, "Advances in the Management of Allergic and Inflammatory Diseases: Highlights from Washington, DC and San Francisco"	174,230 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Annenberg Center for Health Sciences at Eisenhower; Clinical Care Options, LLC	Prostate Cancer Clinical Impact: Tools and Expert Guidance to Inform Optimal Care and Patient Participation in Decisions	45,000
Clinical Care Options, LLC; National Comprehensive Cancer Network	ASCO 2019 ISS - Clinical Guidance for Advanced Prostate Cancer 2019: A Review of Current and Emerging Therapies	120,000
Continuing Education Alliance; Practicing Clinicians Exchange	2019 PCE Oncology Conference Series Segment: Advances in the Treatment of Castration-Resistant Prostate Cancer: More Options for Individualizing Treatment and Improving Outcomes	50,000
Boston Children's Hospital	Precision Medicine Summit: Advanced Medical Genetics and Genetic Counseling Education Program	10,000
Regents University of California Los Angeles	UCLA Fabry Disease Symposium	63,000
Yale School of Medicine, Office of Continuing Medical Education; Dermatology Foundation	2019 DF Clinical Symposia--Advances in Dermatology	5,000 ³
UMA Education Inc., dba Global Education Group; American Society of Transplantation	Cutting Edge of Transplantation: Transplant Summit 2019- No Size Fits All: Uncovering the Potential of Personalized Transplantation	40,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
PlatformQ Health Education, LLC; Montefiore Medical Center/Albert Einstein College of Medicine	Enhancing Urology Care for Patients with Prostate Cancer: An Educational Series with Debates, Cases, Patient Perspectives, and Interactive Lectures	40,000
Specialty Pharma Education Center	Multiple Sclerosis: Advances in Clinical Understanding, Diagnosis & Treatment Strategies for Improved Outcomes	49,750
Medical Learning Institute Inc; PVI, PeerView Institute for Medical Education	PeerView Live, "Recognizing, Diagnosing, and Treating Multiple Sclerosis: The Importance of the Primary Care Clinician in an Evolving Management Paradigm"	35,000
Imedex, LLC; The North American Center for Continuing Medical Education (NACCME)	"Update on Treatment Approaches Across the Multiple Myeloma Spectrum: A Case-Based Discussion; Minimal Residual Disease (MRD) Testing in Multiple Myeloma: The Relevance of Current Technologies and Clinical Applications "	100,000
American Society for Blood and Marrow Transplantation	American Society for Blood and Marrow Transplantation New Investigator Award	65,000
Penn State College of Medicine; PVI, PeerView Institute for Medical Education	PeerView Late Night Video inExchange: Advances in the Management of Moderate-to-Severe Atopic Dermatitis: How Can We Address Unmet Medical Needs in Individual Patients to Optimize Long-Term Outcomes?	219,480 ³
National Association of Managed Care Physicians	Optimizing Switching and Sequencing Strategies for Improved Clinical and Economic Outcomes in the Management of Multiple Sclerosis	45,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
PVI, PeerView Institute for Medical Education; Penn State College of Medicine	Science and Stories at ASCO 2019: New Concepts in Prostate Cancer Care: What Oncologists Need to Know to Optimize Patient Outcomes	100,000
National Association of Managed Care Physicians	New Frontiers in the Treatment and Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at the Role of Emerging Therapies	45,000
Cedars Sinai Medical Center	Emerging Therapies for Prevention and Treatment of Antibody Injury to Allografts 2019	5,000
John Wiley and Sons Inc.	New Frontiers in Cardiovascular Risk Reduction: People with Diabetes and Dyslipidemia	58,000 ³
Cleveland Clinic Educational Foundation	The International Lewy Body Dementia Conference	10,000
EXCEL Continuing Education	Exploring Neurological Manifestations Associated with Gaucher Disease and Pompe Disease	75,245
American Academy of CME, Inc	Rare Disease Clinical Trials: Focus on Lysosomal Storage Disorders	20,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Medical Learning Institute Inc; PVI Peerview Institute for Medical Education Inc.	PeerView inVision, “Improving the Care of Young Patients with Atopic Dermatitis: Recognizing the Differences Between Children, Adolescents, and Adults”	128,250 ³
American College of Rheumatology	2019 ACR Educational Activities	25,000 ³
The France Foundation	Advancements in Atopic Dermatitis: What Does This Mean for Your Practice?	410,100 ³
National Association of Managed Care Physicians	Optimizing Clinical and Economic Outcomes in the Management of Moderate-to-Severe Rheumatoid Arthritis: A Closer Look at the Role of New and Emerging Therapies	45,000 ³
Plexus Communications Rush University Medical Center	Community Oncology Forums: Expert Guidance on the Latest Developments, Treatment Strategies and Emerging Clinical Data in the Management of Multiple Myeloma	50,000
PVI PeerView Institute for Medical Education Inc.; Penn State College of Medicine	PeerView in Clinic - Driving Change: Novel Agent Classes and Next-Generation Therapeutics for Multiple Myeloma	75,000
PVI, PeerView Institute for Medical Education; Penn State College of Medicine	Making Sense of the Multiple Myeloma Treatment Toolkit: New Evidence and Clinical Consensus in Newly Diagnosed and Relapsed Disease	98,700

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Practicing Clinicians Exchange (PCE) Continuing Education Alliance	2019 PCE Oncology Conference Series Segment: Challenges in the Treatment of Relapsed/Refractory Multiple Myeloma	75,000
Medical Learning Institute, Inc.	PeerView Late Night Video inExchange: “Advances in the Treatment of Uncontrolled Persistent Asthma: Expert Insights in Personalizing Patient Care”	181,500 ³
Medical Learning Institute Inc.; PVI, PeerView Institute for Medical Education	PeerView Live at CMSC 2019, “Personalizing Disease-Modifying Therapy for Multiple Sclerosis in the Era of Expanding Options and Potential Markers for Disease Activity and Treatment Response”	100,000
ScientiaCME	Advanced Prostate Cancer: Therapeutic Updates, Best Practices, and Emerging Treatments	20,750
i3Health	Current Challenges and New Opportunities in Hematopoietic Stem Cell Transplant	127,358
Kansas University Endowment Association	Neuromuscular Review Course	40,000
Postgraduate Healthcare Education, LLC; Postgraduate Institute for Medicine (PIM)	Uncontrolled Asthma: Applying Pathophysiology to Improve Patient Outcomes - How Pharmacists Can Help A PHE/Power-Pak Initiative Part 1: Type 2 Inflammation in Asthma: New Understandings and New Treatment Options	154,500 ³
Advancing Knowledge in Healthcare Inc.; RMEI	Care Team Forum: Addressing Real-World Practice Gaps in the Management of RA	411,140

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
The Medical College of Wisconsin, Inc.; Carden Jennings Publishing Co., Ltd.	29th Annual International Prostate Cancer Update (IPCU 29)	15,000
Physicians' Education Resource, LLC (PER)	2019 ONS Symposium: Recognizing and Treating Oncologic Emergencies in the Cancer Patient: What Does the Nurse Need to Know?	120,000
Med Learning Group	A Virtual Reality in Practice View: Decreasing Cardiovascular Risk for Patients with Persistent Hypercholesterolemia	747,955 ³
Postgraduate Institute for Medicine; Tarsus Cardio dba Cardiometabolic Health Congress	Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes	150,000 ³
UMA MLG, LLC	The Virtual Reality Room: Long-Acting Basal Insulins for Patients with Diabetes: Distinguishing Formulations for Individualized Care	619,900
Advancing Knowledge in Healthcare Inc.; RMEI	A Learner Pathway in Moderate-to-Severe AD: Expert Mentoring on Challenging Patient Cases	433,870
National Association for Continuing Education	Conversations in Pulmonary: 2019 Live Virtual Symposium Series the Role of Biologic Therapy in Severe Asthma: A Shifting Treatment Paradigm	108,835 ³
National Association of Managed Care Physicians	Exploring New Pathways and Emerging Data for Better Control and Management in the Personalized Treatment of Severe Asthma	57,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Annenberg Center for Health Sciences at Eisenhower; Clinical Care Options, LLC	CCO Independent Conference Coverage: Clinical Impact of New Rheumatoid Arthritis Findings from APLAR 2019, JAR 2019, and EULAR 2019	40,000 ³
NYU School of Medicine	NYU Langone Seminar in Advanced Rheumatology	25,000 ³
American Thoracic Society	ATS 2019 International Conference - Selected Sessions in Asthma	20,000 ³
Purdue University; Focus Medical Communications	2019-2020 ARTHROS State Society Initiative	50,000 ³
Vindico Medical Education, LLC	3rd Annual Association of Women in Rheumatology: Immunology Bootcamp	100,000 ³
DAVA Oncology	Global Summit on Hematologic Malignancies - Whistler	50,000
University of Chicago	At the Forefront of Hepatology	5,000
The Trustees of Columbia University in the City of New York	The Columbia Renal Biopsy Course	5,000
Distance Learning Network, Inc.	Essentials of Oncology, Solid Organ and Blood/Marrow Transplant Management for the Health Care Team	15,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jan 2019 – 31th Mar 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Scripps Health	Solid Organ Transplant Workshop	15,000
Cleveland Clinic Educational Foundation	2019 Nephrology Update	15,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q1, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Illinois Chapter American College of Cardiology	Chicago Fellows-In-Training Lipid Course	19,550 ³
Pharmacy Times Continuing Education	Improving Patient Access to PCSK9 Inhibitors: The Role of the Retail Pharmacist	95,624 ³
Rutgers, The State University of New Jersey; RedMedEd	Updates in Severe Asthma Management: Recognizing Patient Phenotypes, Incorporating Targeted Therapies	331,776 ³
Horizon CME, Inc.	PCSK9 Inhibitors in the Real-World: Strategies for Optimizing Outcomes in Patients with Hypercholesterolemia	252,050 ³
Preventive Cardiovascular Nurses Association	PCNA's 25th Cardiovascular Nursing Symposium	45,000 ³
Vindico Medical Education, LLC	Preventive Cardiology Fellows Summit: Applying New Options for Optimal CV Risk Management	376,339 ³
Medscape LLC	Therapy Selection for the Patient with Severe Asthma: A Simulation Approach to Uncovering Practice Patterns and Preferences	250,000 ³
Postgraduate Institute for Medicine; RMEI	A Learner Pathway in Severe and Difficult-to-Treat Asthma: Expert Mentoring on Challenging Patient Cases	338,685 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
PRIME Education, LLC	5th Annual Regional Meetings for Providers in Federal and Public Healthcare Sectors: Interprofessional Education on Psoriatic Diseases, Atopic Dermatitis, and Rheumatoid Arthritis	199,000 ³
National Association for Continuing Education	Conversations in Dermatology – Serial Learning Curriculum: Addressing Type 2 Inflammation in Atopic Dermatitis: Individualizing Care Across Populations – An Adaptive Learning Curriculum	350,000 ³
Integrity Continuing Education, Inc.	The Role of the Family Physician in Achieving Optimal Outcomes in Moderate-to-Severe Atopic Dermatitis - Practitioner’s Edge State Society Meeting Series and Quickfire Case Consults	287,300 ³
Projects in Knowledge @Point of Care	Unboxing Shared Decision-Making in Treating Multiple Sclerosis	70,000
RedMedEd Multiple Myeloma Research Foundation; The Pennsylvania State University, College of Medicine	Current Obstacles in Myeloma Management: Debating the Evidence	100,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
American Urological Association	The Evolving Role of the Urologist in Advanced Castration Dependent Prostate Cancer: A Guidelines and Case-based Discussion	50,000
Boston University School of Medicine; Continuing Education Alliance	The Changing Landscape of Dyslipidemia Management: Focus on PCSK9 Inhibitors	375,000 ³
UMA Education dba Global Education Group; Integritas Communications	Pharmacoeconomics and LDL-C Management: Implications for PCSK9 Inhibitors in Clinical Practice	305,210 ³
PRIME Education, LLC	Advancing the Learning Paradigm in Hypercholesterolemia Patient Education Through Social Media, Web Apps, and Patient-Centered Provider Education	384,600 ³
UMA MLG, LLC	Decreasing Cardiovascular Risk for Patients with Persistent Hypercholesterolemia – An Animated Whiteboard View	247,350 ³
Academia Medica Del Sur	Pediatric and Adult Rheumatic Disorders: Current Concepts, Comorbid Diseases and Leading Innovations for Day-to-Day Practice	20,000 ³
PRIME Education, LLC	Engaging Providers and Patients with Moderate-to-Severe Atopic Dermatitis in Collaborative Learning and Shared Treatment Decisions	298,500 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Pharmacy Times Continuing Education	Addressing the Needs of Adolescent Patients with Moderate-to-Severe Atopic Dermatitis	83,910 ³
UT Southwestern Medical Center Medical Logix, LLC	MS Therapy Selection: Improving Clinician Knowledge and Confidence in Therapeutic Decision Making	30,000
i3 Health	Current Standards and Best Practices in the Management of Tumor Lysis Syndrome	63,225
i3 Health	Enhancing Treatment Experiences in Castration-Resistant Prostate Cancer: The Nurse's View	71,575
Med Learning Group	A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma	325,305
EXCEL Continuing Education	Rare Disorders: What the Pediatrician Needs to Know About Fabry Disease and MPS I	74,890

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Integrity Continuing Education, Inc.	2019 Asthma Regional Specialty Fellowship Meetings and Practitioner's Edge On-demand Activity - Appropriate and Effective Use of Novel Oral Corticosteroid-Sparing Therapies to Optimize the Management of Severe Asthma	174,900 ³
PRIME Education, LLC	Achieving Treat-to-Target Goals in Rheumatoid Arthritis: A Collaborative Learning Program for Patients and Provider Teams in Community Rheumatology Practices	240,000 ³
Oakstone Publishing; Answers in CME Inc.	Breakthroughs in Dermatology: New Strategies for Improving Disease Management of Pediatric Atopic Dermatitis	396,815 ³
National Comprehensive Cancer Network	2019-2020 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care	10,000
Annenberg Center for Health Sciences at Eisenhower; Dana Farber Cancer Institute	Master Class for Oncologists 2019	150,000
PRIME Education, LLC	Addressing Undertreatment in ASCVD: ACC/AHA Guidelines and the PCSK9 Quality of Care Gap	444,200 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
PRIME Education, LLC	Building Patient-Provider Partnerships to Improve Treatment Decisions and Outcomes for Patients with Moderate-to-Severe Asthma	298,500 ³
Continuing Education Alliance	Castration-Resistant Prostate Cancer: Integrating New Strategies into Clinical Practice	60,000
i3 Health	Nursing Essentials in Castration-Resistant Prostate Cancer: A Plenary Session at the 3rd Annual GLAONS Oncology Care Summit	30,000
American Society of Transplantation	The 2019 Fellows Symposium on Transplantation	40,000
Oakstone Publishing; Answers in CME Inc.	A Crucial Equation to Reduce Future CV Events: A Multi-Pronged Approach to LDL-C Lowering	411,552 ³
PRIME Education, LLC	New Data and Guidelines in Lipids for Therapeutic Selection and Patient Care Optimization: A CME Program for PRIME's Weekly Webinar Series	256,000 ³
Medical Learning Institute, Inc.; PVI, PeerView Institute for Medical Education	PeerView Video in Session, "The Latest Evidence on Treatment for Uncontrolled Persistent Asthma: Breaking News from Dallas"	148,980 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Integrity Continuing Education, Inc.	2019 Pediatric State Society Meetings, Reveal Fold Decision Aid Card, and Clinical Commentary - Advances in Management of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents	347,000 ³
Rheumatology Nurses Society, Inc.	12th Annual RNS Conference	25,000 ³
The Omnia Prova Education Collaborative (TOPEC); Prova Education, Inc.	Rare Blood Disorders and Hemoglobinopathies: Updates on Diagnosis and Treatment in the Emergency Department	80,000
EXCEL Continuing Education	Fourth Annual Blood Disorders/Complications Conference	10,000
Projects in Knowledge	Ask the Expert: Hypercholesterolemia	125,000 ³
University of Maryland, Baltimore	Understating the Link Between Gaucher Disease and Marlon: From Rare Disease to Common	3,300
National Kidney Foundation	Regional Renal Grand Rounds: Glomerular Disease	5,000
University of California Irvine	9th Annual UC Irvine Health Neuromuscular Colloquium	20,000
Projects in Knowledge	Pulmonology @Point of Care: A Focus on Moderate to Severe Asthma	200,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
American Academy of PAS; Medical Logix, LLC	New Approaches to the Management of Atopic Dermatitis	138,500 ³
American Academy of Physician Assistants	AAPA 2019 - Rheumatology Track	10,000 ³
Med Learning Group	A VR View: Severe Uncontrolled Asthma: Phenotypes, Endotypes, and Treatment Response Decisions	293,785 ³
St. Joseph's University Medical Center	Multiple Sclerosis	1,500
USF Health	Staying Up to Date with Advances in the Management of Multiple Sclerosis	100,000
The Board of Regents of the University of Nebraska	2019 Update on the Diagnosis and Management of Multiple Sclerosis and Demyelinating Diseases Symposium	7,500
Postgraduate Institute for Medicine RMEI	AliveSim: An Immersive Virtual Patient Experience in Multiple Sclerosis	50,000
The Cleveland Clinic Educational Foundation	Mellen Center Update in Multiple Sclerosis (MS)	5,000
Vindico Medical Education, LLC	MS Forum [®] VI: Applying the Latest Data and Advanced Communication to Individualize Treatment and Improve Quality Care	75,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
AKH Inc, Advancing Knowledge in Healthcare; MT Advanced Continuing Education Specialist, LLC.	Multiple Sclerosis Management: How Early Diagnosis, General Wellness Efforts and Improved Adherence to Therapies better Patient Outcomes.	10,000
American Urological Association	AUA2019 Prostate Cancer Courses and Enduring Activities	130,000
Medscape, LLC	Clinical Advances in Multiple Myeloma: Year 5	350,000
American Society of Clinical Oncology	2019 ASCO Annual Meeting Genitourinary Cancer Tracks Bundle (Prostate and Nonprostate)	20,000
Plexus Communication; Rush University Medical Center	Multiple Myeloma Rounds® - 2019 'Advancing Care and Optimizing Outcomes '	30,995
Physicians' Education Resource, LLC (PER)	Oncology Best Practice™: Optimizing Outcomes Through Stem Cell Mobilization: Equipping Transplant Centers to Make the Most of ASCT	223,315
Physicians' Education Resource, LLC (PER)	Cancer Summaries and Commentaries™: Report from Chicago on Advances in Genitourinary Cancers	25,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Research to Practice	Year in Review — A Five-Part Multi-tumor Regional CME Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers: Genitourinary Cancers Module	30,000
University of Illinois at Chicago College of Pharmacy	Illinois Transplant Pharmacists Association Symposium	8,000
National Medical Association	NEPHROLOGY SESSION Clinical Nephrology: Renal Recovery and Replacement for the Generalist and Specialist. Mitigating High Morbidity and Mortality Rates from Kidney Disease in At-Risk Patients	125,000
Postgraduate Institute for Medicine; Enquiring Minds, LLC	Lysosomal Storage Disorders - Common Presentations of Uncommon Diseases: Expert Guidance on Early Identification and Therapeutic Optimization	89,905
EXCEL Continuing Education	Gaucher Disease and Niemann Pick A/B Diseases: The Link to Hematologic Malignancies	316,180
Boston University School of Medicine; Continuing Education Alliance dba Practicing Clinicians Exchange (PCE)	Moderate to Severe Asthma: Applying New Options for Improving Outcomes	295,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
i3 Health; USF Health	Optimizing Therapeutic Strategies in Castration-Resistant Prostate Cancer	100,000
Med-IQ, Inc.	Current Practices in AF Management: Are Guideline-Based Options Driving Better Outcomes?	237,737 ³
Boston University School of Medicine, CME	Practical Approach to Electromyography and Neuromuscular Disorders Conference	7,500
Horizon CME, Inc.; RealCME	Making A Difference for Your AD Patients: Pathways to Improving Outcomes in AD and its Comorbidities	299,650 ³
Medscape LLC	Equipping the Primary Care Physician for the Management of Patients with Atopic Dermatitis: A Call to Awareness and Action	138,450 ³
UMA MLG, LLC	A 3D View - Inhibiting Structural Damage in Rheumatoid Arthritis: Targeting IL-6 for Reducing Inflammation - A Component of the CATALYST Initiative	299,650 ³
Carden Jennings Publishing Co., Ltd.; The Medical College of Wisconsin, Inc.	Grand Rounds in Urology Conference Reviews: Highlights from the 24th Southwest Prostate Cancer Symposium	30,000
Physicians' Education Resource, LLC	2019 ASCO Direct Highlights	25,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Horizon CME, Inc.	Understanding the Rapidly Evolving Science and Best Practices in Multiple Myeloma	98,700
National Lipid Association; PlatformQ Health Education, LLC	Role of PCSK9 Inhibitors in the Management of Patients with Familial Hypercholesterolemia	150,000 ³
University of Cincinnati; MCM Education	Precision Medicine in Severe Asthma	130,000 ³
The Omnia Prova Education Collaborative (TOPEC); Prova Education, Inc.	Advances in Asthma: Keeping Pace with the Evolving Treatment Paradigm—2019 Conference Coverage	284,000 ³
Boston University School of Medicine; Continuing Education Alliance dba Practicing Clinicians Exchange (PCE)	Long-term Management Strategies for Moderate to Severe Atopic Dermatitis: What Clinicians Need to Know to Optimize Patient Outcomes	325,000 ³
Postgraduate Institute for Medicine; Talem Health, LLC	Rural Health Clinical Congress 2019 - Improving the Assessment and Management of Uncontrolled Asthma in Rural and Underserved Communities	188,394 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Apr 2019 – 30th Jun 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Integrity Continuing Education, Inc.	Practitioner’s Edge State Society Meeting Series and CME Audit and Feedback Practice Assessment - Investigating Critical Issues in the Management of Patients with Severe Asthma	268,400 ³
Consortium of Multiple Sclerosis Centers; International Organization of MS Nurses	2019 MS Counseling Points, CE Webinar Series for MS Nurses	48,800
Consortium of Multiple Sclerosis Centers; Spire Learning, LLC	Practical Approaches for MS Infusion Therapies	60,000
American Academy of CME, Inc	Rare Disease Clinical Trials and Expanded Access: Challenges and Opportunities for Clinicians and Patients with Hematologic, Non-cancerous Disorders	20,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q2, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Association of Black Cardiologists, Inc.	Conversations in Cardiology 2019 Live Virtual Symposium - Reducing Cardiovascular Risk: Making Sense of the Latest Data and Guidelines	121,500 ³
Global Education Group; Integritas Communications	Marching Forward in Atopic Dermatitis: Digging Deep on Shared Decision Making	299,845 ³
UMA MLG, LLC	Improving the Management of Patients with Severe Uncontrolled Asthma	138,245 ³
National Association of Managed Care Physicians	Therapeutic Switching and Sequencing in Multiple Sclerosis: Implementing Expert Strategies for Improved Clinical and Economic Outcomes	45,000
Physicians' Education Resource, LLC (PER) Pharmacy Times Continuing Education	Neurology Consultations: Coordinating Care Between the Neurologist and Pharmacist in Multiple Sclerosis Treatment	54,000
Rush University Medical Center; ASiM CE, LLC	Individualizing Therapy for Hemophilia A: Evaluating the Clinical Implications of Scientific Advances in Treatment and Dosing	150,000
PRIME Education, LLC	Shared Management Approaches in Primary Care Settings to Ensure Best Treatments and Outcomes for Patients with Atopic Dermatitis	248,900 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Postgraduate Institute for Medicine; Talem Health, LLC	Rural Health Clinical Congress 2019 - Atopic Dermatitis Management in Rural and Underserved Communities: Overcoming the Distance for Improved Dermatology Care	188,394 ³
Medscape LLC	Clinical Advances in Moderate-to-Severe Atopic Dermatitis: Connecting Providers and Patients: Virtual Patient Simulations	431,000 ³
Medscape LLC	Clinical Advances in Moderate-to-Severe Atopic Dermatitis: New Data for Clinician and Patients	527,100 ³
Medscape, LLC	Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders	100,000
Medscape LLC	Dyslipidemia, Mortality, and Emerging Evidence: Can PCSK9 Inhibitors Address the Challenge?	228,000 ³
Med Learning Group	Addressing Management Challenges Posed by Patients with Severe Uncontrolled Asthma in Clinical Practice	249,800 ³
National Association of Managed Care Physicians	Integrating the Latest Therapeutic Advances to Optimize Patient Outcomes in Relapsed/Refractory Multiple Myeloma	28,700

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Physicians' Education Resource, LLC (PER)	37th Annual CFS Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow [®]	50,000
Annenberg Center for Health Sciences at Eisenhower; Prostate Cancer Education Council	2019 SUNA Advanced Prostate Cancer Grant	30,000
Research to Practice	The 1st Annual Oncology Nursing Retreat — A Pilot Multitumor CNE Conference: Prostate Cancer Module	15,000
Rush University Medical Center; Plexus Communication	Community Hematology Forums: Expert Opinions on Advances in the Management of Inherited Bleeding Disorders	50,000
University of Texas Health Science Center San Antonio School of Medicine-Office of CME; Encore Medical Education, LLC	Highlights of International Society on Thrombosis and Hemostasis Congress 2019	40,000
Medscape LLC	Conference Coverage Series (Part 2 – ERS): Novel Treatment Strategies for Asthma and Its Comorbidities	269,500 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
American College of Allergy, Asthma & Immunology; Intermountain West Allergy Association	IWAA 2019 22nd Annual Scientific Session	5,000 ³
Physicians' Education Resource, LLC (PER)	Clinical Interchange: Addressing Cultural Competencies within Special Populations in MS	50,000
Medical Learning Institute Inc.; PVI PeerView Institute for Medical Education Inc.	PeerView in Session from ECTRIMS 2019, "Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings from Stockholm?"	50,000
Postgraduate Institute for Medicine; Enquiring Minds, LLC	Integrating Real-World Evidence into Treatment Decisions for Relapsing MS: Expert Guidance on Challenging Cases	35,000
i3 Health	Keeping Pace with Evolving Management Strategies in Castration-Resistant Prostate Cancer	99,725
American Urological Association	The AUA Expert Exchange Podcast: Discussions About Managing GU Cancer	100,000
American Academy of CME, Inc	Management of Multiple Myeloma Through an Interprofessional Approach: Utilization of Treatment Combinations and Sequencing of Regimens	121,285

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Imedex, LLC; North American Center for Continuing Medical Education (NACCME)	Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges	50,000
Medical Learning Institute Inc.; PVI, PeerView Institute for Medical Education	PeerView Live Masterclass & Practicum at ACMG 2020, “Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency”	251,910
PeerVoice America Limited	Recognizing and Addressing Burden of Disease in Adolescents with Moderate-to-Severe AD	201,604 ³
Continuing Education Alliance dba Practicing Clinicians Exchange (PCE)	Navigating the Complexities of Relapsed/Refractory Multiple Myeloma: Novel Treatment Strategies for Improving Outcomes	100,000
EXCEL Continuing Education	A Primer for Family Practice and PCPs on Rare Diseases: Focusing on Pompe and MPSI	75,000
Oakstone Publishing; Answers in CME Inc.	Putting Theory into Practice in Managing Complex Patients with Atopic Dermatitis	350,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Oakstone Publishing; Answers in CME Inc.	Precision Medicine in Rheumatology: The Emergence of Biomarker Analysis to Guide Treatment Selection in RA	170,000 ³
Consortium of Multiple Sclerosis Centers; Catamount Medical Education	What Is Disease Modifying Therapy? A Game-Based Learning Experience on Evidence-Based Disease Modification in Multiple Sclerosis	50,000
The University of Chicago; Miller Medical Communications LLC	Lessons Learned from Newborn Screening for Pompe Disease and Mucopolysaccharidosis Type 1: Early Intervention Influences Outcomes	232,750
National Association of Managed Care Physicians	What's New in the Evolving Treatment Paradigm in Moderate-to-Severe Rheumatoid Arthritis (RA): Novel Therapies for Improved Clinical and Economic Outcomes	45,000 ³
Research to Practice; Penn State College of Medicine	Prostate Cancer Update — An Enduring Audio, Video, Podcast, Web and Mobile Interview Program for Medical Oncologists and Urologists: 2019 Edition	50,000
Plexus Communication; Society of Urologic Nurses and Associates	Prostate Cancer: Latest Treatments and Emerging Therapies	35,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Practice Point Communications; Rush University Medical Center	Evolving Treatment Strategies in Prostate Cancer	80,000
Regents of the University of Minnesota	Transplant Immunosuppression 2019: Hot Topics	75,000
Penn State College of Medicine	Inaugural Kidney Transplantation Symposium	4,000
University of Massachusetts Medical School	Multiple Sclerosis Practice Update “New Approved Therapies and Biomarkers Updates in Multiple Sclerosis”	20,000
Mayo Clinic College of Medicine Mayo Clinic Arizona	Mayo Clinic Acute and Chronic Leukemias 2019	10,000
Physicians Education Resource LLC (PER); University of Cincinnati	Medical Crossfire®: Exploring the Latest Advancements in Prostate Cancer Care	75,000
University of Virginia, Continuing Medical Education	Therapeutic Apheresis Academy	10,000
American Society of Transplant Surgeons	13th Annual Surgical Fellows Symposium	75,000
International Transplant Nurses Society	ITNS 2019 Transplant Nursing Symposium: Transplant Nursing in the 21st Century	12,500

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Duke University Health System University of North Carolina at Chapel Hill	10th Symposium on Hemostasis: Coagulation, Platelets and Transfusion Medicine	20,000
EXCEL Continuing Education	Assessing Bone Manifestations in Gaucher Disease	85,220
Medical Learning Institute Inc.; PVI, PeerView Institute for Medical Education	PeerView inVision, “Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis with Nasal Polyps”	148,250 ³
PRIME Education, LLC	Supporting Allergy/Immunology and Pulmonology Teams in Resolving Patient Access Issues to Asthma Therapies: An Initiative with the American Academy of Allergy, Asthma, and Immunology (AAAAI) and the Academy of Managed Care Pharmacy (AMCP)	286,600 ³
PRIME Education, LLC	Atopic Dermatitis Across the Lifespan: Interdisciplinary Expert Perspectives on New Treatment Options - A PRIME-AMCP Educational Program for Managed Care and Specialty Pharmacy Professionals	286,200 ³
Annenberg Center for Health Sciences at Eisenhower	Immunotherapy Advances in RRMM: An Educational Journey™	86,555 ³
American Society for Transplantation and Cellular Therapy	2020-2022 American Society for Transplantation and Cellular Therapy New Investigator Award	65,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
UMA MLG, LLC	Optimal LDL-C Reductions in Patients with Atherosclerotic Cardiovascular Disease: Maximizing Clinical Benefit within the Department of Veteran Affairs	149,905 ³
Society for Inherited Metabolic Disorders (SIMD)	2019 North American Metabolic Academy	25,000
Advancing Knowledge in Healthcare Inc.; RMEI	First, Know Thyself: Assessing for Clinical Excellence in Chronic Rhinosinusitis with Nasal Polyps	214,105 ³
Med Learning Group	Targeting Inflammation: Biologic Immunomodulators For Moderate-to-Severe Chronic Rhinosinusitis with Nasal Polyps - An Animated Whiteboard View	215,100 ³
Advancing Knowledge in Healthcare Inc.; RMEI	Pediatric Asthma: Evidence-Based Approaches in Poorly Controlled Disease	85,000 ³
Advancing Knowledge in Healthcare Inc.; RMEI	Improved Care for Patients with Moderate-to-Severe Asthma: Reflecting on Errors and Missed Opportunities	178,530 ³
UMA MLG, LLC	A Virtual Reality View - New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis	498,420 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
UMA MLG, LLC	The Virtual Reality Room: Targeting Type 2 Inflammation in Atopic Diseases: The Role of Interleukin Inhibitors	649,700 ³
AKH Inc, Advancing Knowledge in Healthcare MT; Advanced Continuing Education Specialist, LLC.	Neurology and Movement Disorders Symposium: The Common and Uncommon	7,000
Physicians' Education Resource, LLC (PER)	Cancer Summaries and Commentaries™: Report from Orlando on Advancements in Multiple Myeloma	50,000
Physicians' Education Resource, LLC (PER)	2020 ASCO GU Symposium: Selecting and Sequencing Therapies Through the Prostate Cancer Continuum: An Expert Tumor Board Discussion	150,000
American Society of Transplant Surgeons	20th Annual State of the Art Winter Symposium: Honoring our History, Forging our Future	110,913
Affinity CE; LDRTC	Genetic Rare & Immune Disorders Symposium (GRIDS) 2019 - Neurological Outcomes in Lysosomal Storage Disorders	85,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Continuing Education Alliance dba Practicing Clinicians Exchange (PCE); Association of Women in Rheumatology (AWIR)	Collaborative Care: A Better Model for Rheumatology Practice	65,000 ³
Scientia CME	Hemophilia A: Optimizing Pharmacotherapeutic Management Strategies	19,200
WebMD Global; World Allergy Organization (WAO)	The Changing Landscape of Severe Asthma: The Role of IL4/13 Dual Targeting—International Perspectives for OUS MDS: An Initiative Developed in Partnership with the World Allergy Organization (WAO)	300,000 ³
University of Nevada, Reno School of Medicine; Foundation for Research and Education in Dermatology	2019 Fall Clinical Dermatology Conference Live and Enduring CME Satellite: A Look at the Recent Clinical Advancements Made in Atopic Dermatitis	150,000 ³
Postgraduate Institute for Medicine; Global Academy for Medical Education	Diving Beneath the Surface to Improve and Individualize Care in Moderate-to-Severe Atopic Dermatitis: 2019 Live and Enduring Activities	300,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Scientia CME	Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies	19,200
Rush University Medical Center	State of the Art Monitoring and Treatment of Hyperlipidemia and Cardiac Risk	15,000 ³
UMA MLG, LLC	IMPACT Initiative: Improving the Care of Patients with Persistent Hypercholesterolemia by Decreasing Cardiovascular Risk Using PCSK9 Inhibitors: A Comprehensive Infographic View	249,125 ³
Cedars-Sinai	2019 Pediatric State of the Art	5,000
Physicians' Education Resource, LLC (PER)	Clinical Briefings™: Diagnosing and Treating MPS 1: Opportunities to Improve Prognosis	86,900
National Medical Association	NMA Asthma Summit Asthma in Urban Cities Initiative “Back to Basics for Patients with Asthma”	20,000 ³
Medical College of Wisconsin Carden; Jennings Publishing Co., Ltd.	Stem Cell Mobilization for Hematologic Malignancies: Choosing the Best Option in the Emergence of New Mobilization Strategies	84,327

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Children's Hospital Corporation DBA Boston Children's Hospital, Division of Genetics and Genomics	Metabolism Conference Series	7,500
The Regents of UC/Office of Cont Med Educ	UCLA Peritoneal Dialysis Symposium: Dawn of a New Era for Kidney Health	10,000
Medical Education Resources Impact Education, LLC	Multiple Sclerosis Update: Clinical, Economic, and Patient-Centric Strategies for Managed Care and Specialty Pharmacy Professionals	150,000
National Association of Managed Care Physicians	Optimizing Treatment Regimens, Switching and Sequencing in Multiple Sclerosis: Leveraging Data to Make Informed Decisions in Managed Care	50,000
National MPS Society; Shapiro Neuropsychology Consulting, LLC	MPS Cognitive Master Class	25,000
ANA NY; ISONG	2019 ISONG World Congress - Transforming Health Through Genomic Nursing	2,500
Med-IQ	On the Frontlines of Diagnosis: Preventing Diagnostic Delays in MPS I and Other LSDs	99,964

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Postgraduate Institute for Medicine; Enquiring Minds, LLC	Newborn Screening for MPS 1 and Pompe Disease: Expert Guidance on Overcoming Barriers to Early Diagnosis and Management	142,870
Med-IQ	Recent Changes in Newborn Screening: What, When, How, and Why	147,121
National Hemophilia Foundation	Workshop on Novel Technologies and Gene Transfer for Hemophilia 2019	20,000
Center for Innovative Management of PKD, Toronto General Hospital, University Health Network; Agence Liv Inc.	2019 Toronto PKD Scientific Day	51,508
National MPS Society; RareLife Solutions, Inc.	National MPS Society Physician Masterclass	60,000
The France Foundation	Characterizing and Screening for Lysosomal Storage Disorders in Newborns: A Grand Rounds Series	150,000
Emory University	2019 Center for Functional Evaluation of Rare Variants (CFERV) Conference on GRIN variants	6,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Penn State College of Medicine Rockpointe Corporation	Reducing Disease Activity in Multiple Sclerosis: Keeping Up with Recent Advances	102,000
American Association of Nurse Practitioners; MCM Education	Diagnosing and Managing MS: A Guide for Nurse Practitioners	50,000
PVI, PeerView Institute for Medical Education; Medical College of Wisconsin	PeerView Live at the 2020 TCT Meetings, Changing Perspectives on Multiple Myeloma and ASCT: Clinical Decision-Making, New Evidence, and Expanding Therapeutic Options	120,460
Plexus Communications; Rush University Medical Center	Navigating the Prostate Cancer Disease Continuum: Evolving Strategies in the Management of HSPC and CRPC	70,000
Physicians' Education Resource, LLC (PER)	2020 ASCO Symposium: Optimizing Outcomes in Prostate Cancer: Matching Treatment to Patient in the Modern Era	125,000
Physicians' Education Resource, LLC (PER)	2020 AUA Symposium: Personalizing Care in Prostate Cancer: Current Trends and Updates for the Practicing Urologist	105,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Independent Medical Education Grants

1st Jun 2019 – 30th Sep 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
The Omnia-Prova Education Collaborative, Inc. (TOPEC); Medtelligence	Heart-to-Heart Clinical Intensive: Considerations for Rhythm Control Post CABANA	259,060 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q3, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
National Women’s Health Resource Center	Women & Cardiovascular Disease: Raising Awareness and Addressing Prevention Strategies	50,000 ³
Oakstone Publishing; Answers in CME Inc.	A Heart to Heart About the Recent Guidelines in Dyslipidemia: Guidance for Clinical Practice	168,750 ³
Association of Black Cardiologists, Inc.	Pushing the Threshold of Lipid Lowering: Incorporating the Evolving Database into Practice	255,583 ³
ThinkGenetic Foundation	Fabry Disease Neurology Lunch and Learn in Lafayette	5,950
ThinkGenetic Foundation	The A-B-Cs of GENETICS: A Genetics Primer for Healthcare Advocates in Medically Underserved Parishes of Louisiana	11,975
Medscape LLC	Integrating Novel Therapies in Severe Asthma: A Unique Program with Virtual Simulation	445,000 ³
Postgraduate Institute for Medicine; Talem Health, LLC	Rural Health Clinical Congress 2019 - Improving Lipid Management in Rural Primary Care	188,174 ³
Hemedicus, Inc.	Managing Benign Hematology in the Community Setting	25,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Carden Jennings Publishing Co; The Medical College of Wisconsin, Inc.	28th Perspectives in Urology: Point Counterpoint	10,000
Preventive Cardiovascular Nurses Association	Cardiovascular Nursing Certificate: Supporting Nurses Across the U.S. in Critical Knowledge and Behaviors in the Prevention and Management of CVD and Stroke	35,000 ³
Cedars-Sinai	9th Annual Symposium on Lysosomal Storage Disorders	20,000
PVI, PeerView Institute for Medical Education; Purdue University	PeerView Live at ASGO GU 2020, “Mapping the Pathways to Better Patient Outcomes in Prostate Cancer Personal Insights and Guidance from the Patient Casebook”	100,308
Medical Learning Institute Inc.; PVI PeerView Institute for Medical Education Inc.	PeerView Live Masterclass at ACTRIMS Forum 2020, “Navigating the Evolving Management Paradigm Across Multiple Sclerosis Phenotypes in the Age of Potential Prognostic and Predictive Biomarkers”	125,000
University of California San Francisco	UCSF Otolaryngology Update 2019	10,000
Cedars-Sinai	Latest Updates on Neuroimmunology: 4th Annual Conference for Healthcare Professionals and Patients	10,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² “Funding Amount” is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. “Funding Amount” does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Rheumatology Nurses Society; MedCaseWriter, Inc.	Rheumatology Nurse Practice: Managing Rheumatoid Arthritis Throughout the Lifespan	43,750 ³
Clinical Care Options, LLC; USF Health Professions Conferencing Corporation	Understanding New Therapeutic Strategies in Prostate Cancer: Expert Guidance and Tools to Inform Optimal Care	25,000
Clinical Care Options, LLC; USF Health	Honing Treatment Strategies in Advanced Prostate Cancer: Latest Evidence to Guide Clinical Decisions in Community Practice	40,000
P\S\L Group Luxembourg Sarl - DBA PeerVoice	Warming Up to Novel Approaches for Primary Cold Agglutinin Disease: Strategies for Early Diagnosis and Treatment	113,085
WebMD Global LLC	How Would you Manage this Patient with aTTP?	307,150
The George Washington University; The George Washington School of Medicine and Health Sciences	The 12th Philadelphia Prenatal Conference	8,000
Physicians' Education Resource, LLC (PER)	Medical Crossfire®: Optimizing the Treat-to-Target Approach in Rheumatoid Arthritis: Translating Clinical Evidence into Effective Shared Decision-Making	75,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Physicians' Education Resource, LLC (PER)	Clinical Summaries and Commentaries™: Updates from Atlanta – Therapeutic Advancements in Rheumatoid Arthritis	43,750 ³
Research to Practice; Penn State College of Medicine	Addressing Current Questions and Controversies in the Management of Patients with Prostate Cancer - An Independent Satellite Symposium (ISS) Held as a Premium Ancillary Educational Event During the 2020 Genitourinary Cancers Symposium	95,000
Regents of the University of Colorado; American Thyroid Association	89th Annual Meeting of the American Thyroid Association	75,000
University of Rochester	24th Annual Asthma and Allergy Update	5,000 ³
Postgraduate Institute for Medicine; Integritas Communications	Airing It Out: A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis with Nasal Polyps	332,355 ³
PER Global, LLC	Cancer Summaries and Commentaries™: Update from Barcelona—Advances in the Treatment of Genitourinary Cancers	40,000
ScientiaCME	Advanced Prostate Cancer: Optimizing Management Strategies	20,500
Physicians' Education Resource, LLC (PER)	2020 EHA Symposium: Exploring Novel Antibody-Based Treatments for Relapsed/Refractory Multiple Myeloma: How the Experts Think & Treat	300,000

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Oakstone Publishing; Answers in CME Inc.	Elevating Cardiometabolic Management with Comprehensive Collaborative Care	140,000 ³
PRIME Education, LLC	A Paradigm Shift in Atopic Dermatitis? Interdisciplinary Expert Debates on Specialty Pharmacy Considerations	242,300 ³
Total CME, Inc.	ISTH Television at the 2019 Congress: Bringing Clinical Science to Life	31,412
Amedco MedNet	Symposium on Changing Treatment Landscape of Multiple Sclerosis with Disease-modifying Agents and Monoclonal Antibodies	20,000
Academic CME LLC	ESMO 2019: Clinical Updates for the Optimal Management of Patients with Prostate Cancer	70,000
National Jewish Health	42 Annual National Jewish Health Pulmonary and Allergy Update	10,000 ³
National Comprehensive Cancer Network	NCCN 2020 Annual Conference: Celebrating 25 Years of NCCN	40,000
EXCEL Continuing Education	Unmasking Rare Disorders: What the P.A. Needs to Know	97,280
American Academy of CME, Inc	Fabry Disease Highlights from WORLD Symposium	33,250

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.

Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Annenberg Center for Health Sciences at Eisenhower	Diagnosing Rare Diseases Brings New Treatments to Patients: Education for Advanced Practice Providers	100,000
Postgraduate Institute for Medicine; Enquiring Minds, LLC	Rare Diseases and the Non-Physician Provider: Expert Guidance on Recognizing and Managing Lysosomal Storage Disorders	99,950
American Academy of CME, Inc	Gaucher Disease Highlights from WORLD Symposium	33,250
Medscape LLC	Treatment of CRS With Nasal Polyps: Is Your Knowledge Current?	110,000 ³
Oakstone Publishing; Answers in CME Inc.	Hitting the Mark with Biologic Asthma Treatment: The Role of Biomarkers	212,500 ³
AKH Inc., Advancing Knowledge in Healthcare; Tarsus Cardio dba South Beach Symposium	Masters of Pediatric Dermatology	3,700 ³
AKH Inc., Advancing Knowledge in Healthcare; Tarsus Cardio dba South Beach Symposium	Masters of Pediatric Dermatology Virtual Highlights	4,000 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.



Independent Medical Education Grants

1st Oct 2019 – 31th Dec 2019

Sanofi US and its affiliate Genzyme Corporation are committed to supporting independent medical education activities in therapeutic areas in which the Company is involved, for healthcare professionals, patients, and consumers to improve patient care and health outcomes in therapeutic areas in which the Company is engaged. Sanofi US and Genzyme Corporation are part of the Sanofi Group, a global pharmaceutical company.

Recipient Name(s) ¹	Activity Title	Funding Amount ²
Oakstone Publishing; Answers in CME Inc.	Replacing Walls with Open Doors: Elevating the Management of Severe Asthma Through Collaborative Care	218,835 ³

¹ Applicant names are provided by the requestor. If applicants apply as a group for a single educational activity; all applicants may be not be identified above. The Company funds other educational activities (including fellowships and non-physician and patient education); all of which do not appear on this report but appear on other reports on this site.

² "Funding Amount" is the amount that the Company funded during Q4, 2019 identified above based upon an agreement. Recipients are required to return any unused funds. Information on unused funds returned by the applicant on activities are not reported. "Funding Amount" does not include funds that may have been provided by other affiliated Sanofi Company Entities, (e.g., Sanofi Pasteur)

³ Collaboration (Shared) Funding – is the full amount of a grant funded under an agreement with Regeneron, some or all of which may be shared between the collaborating entities.